Company Overview and News

2
E&P Bottom Of The Barrel Club #18-2: The Market Plays 'Whack-A-Mole'

2018-04-16 seekingalpha
After a 20% run-up in Club stocks in January, prices declined the rest of the quarter by -25%, with the Club finishing with an average return of -9%.
Upvote Downvote

1
XCO / EXCO Resources, Inc. FORM 10-K (Annual Report)

2018-03-15 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
XCO / EXCO Resources, Inc. FORM 8-K (Current Report)

2018-03-01 sec.gov
Form 8-K

 

 

UNITED STATES

Upvote Downvote

2
E&P Bottom Of The Barrel Club #18-1: Wipeout!

2018-02-20 seekingalpha
After a nice "Santa rally" and "January effect," Bottom of the Barrel companies' stock prices have hit a very rough patch that essentially wiped out recent gains.
Upvote Downvote

 
XCO / EXCO Resources, Inc. / FAIRFAX FINANCIAL HOLDINGS LTD/ CAN - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
    SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G/A (Amendment No. 4)*   Under the Securities Exchange Act of 1934   EXCO Resources, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 269279402 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d)   * The remainder of this c
Upvote Downvote

 
XCO / EXCO Resources, Inc. / FAIRFAX FINANCIAL HOLDINGS LTD/ CAN - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
    SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G/A (Amendment No. 4)*   Under the Securities Exchange Act of 1934   EXCO Resources, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 269279402 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d)   * The remainder of this c
Upvote Downvote

5
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update

2018-02-16 seekingalpha
Fairfax Financial's largest five stakes are Blackberry, Resolute Forest Products, Kennedy Wilson, Intrepid Potash, and USG. They together account for ~85% of the US long assets.
Upvote Downvote

6
My Insights Into Current Bankrupt Companies

2018-02-08 seekingalpha
There has been a lot news since my last article on bankrupt companies. This includes a current trend to liquidate assets instead of creating a new viable company to continue operations. It seems what issues that caused the bankruptcy cannot be reduced enough in the Ch.11 process to support a newly restructured business model.
Upvote Downvote

 
US Natural Gas Consumption Could Help Natural Gas Bulls

2018-02-02 editors.aws.marketrealist
According to PointLogic, US natural gas consumption fell 2% to 81.9 Bcf (billion cubic feet) per day on January 25–31, 2018. US natural gas consumption also decreased 1.9% year-over-year. The decline in consumption is bearish for natural gas prices.
Upvote Downvote

4
E&P Investors: 18+ Things To Watch In 2018 (Part 2)

2018-01-30 seekingalpha
In Part 1 of this article, I discussed my own views on certain macroeconomic factors that investors should follow in 2018, including global and U.S production and pricing levels.
Upvote Downvote

 
XCO / EXCO Resources, Inc. FORM 8-K (Current Report)

2018-01-25 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2018     EXCO RESOURCES, INC. (Exact name of registrant as specified in its charter)   Texas   001-32743   74-1492779 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.
Upvote Downvote

1
FirstEnergy Soars as Elliott Leads $2.5 Billion Investment - Bloomberg

2018-01-22 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Energy Recap: Tackling Renewable Energy's Biggest Problem - Storage

2018-01-20 seekingalpha
Every Friday, Seeking Alpha provides a roundup of insightful opinion and analysis articles in the energy sector.
Upvote Downvote

 
Weather Extremes, Natural Gas Climatech And The Ski Season

2018-01-17 seekingalpha
Record EIA draw of -369 last week and more cold weather into February helps natural gas prices break resistance.
Upvote Downvote

 
XCO / EXCO Resources, Inc. FORM 8-K (Current Report)

2018-01-17 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 15, 2018     EXCO RESOURCES, INC. (Exact name of registrant as specified in its charter)       Texas   001-32743   74-1492779 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 269279402